Pharmaceutical Executive
With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.
Attending events and conferences are one way to keep up to date on the current issues in your functional area. There is no limit to the types of conferences you can choose-smaller one-day workshops to large, multi-track conferences with exhibit floors, to even more targeted user group events for companies that use that technology
Lisa Henderson
vendor’s products. From January to June, the conference season is in high gear and for Pharmaceutical Executive, that season means getting out and learning alongside attendees to uncover new trends, revisit the tried and true for fresh takes, and network for new ideas to present to our readers.
This year has seen the team in San Francisco for the J.P. Morgan Healthcare Conference; Vienna for the DIA European meeting; Barcelona and Philadelphia for double-doses of eyeforpharma; Philadelphia for CBI’s Annual Life Sciences Accounting & Reporting Congress; and DC for CBI’s 16th Annual PCC 2019/Pharmaceutical Compliance Congress. Next up is BIO in Philadelphia followed by a first-half season close with DIA in San Diego.
That’s not to say you still can’t find some conference gems hidden in the summer calendar, much like the seashells you save from your vacation. But vacations and summer schedules do make the conference schedule a little harder to pack and fold for the busy professional.
Our visits to the conference early season produced some great content. First up, a series of videos from both eyeforpharma events, which should soon start popping up on our YouTube channel. European Editor Julian Upton interviewed executives from Propeller Health, ALK Pharmaceuticals, LEO Pharma, S3 Connected Health, and Caribou Bio in Barcelona. In Philadelphia, Associate Editor Christen Harm and I split interviewing duties, with Christen tackling marketing and sales trends with executives from GSK, while I interviewed leaders from Alkermes, Shire/Takeda, and AbbVie on marketing to integrated delivery networks (IDNs); patient advocacy; and analytics.
Also, a shout-out to the advertisers that helped support these editorial interviews by sponsoring their own interviews on-site at eyeforpharma. They include: Aptus Health, Cognizant, Philips Medisize, VMS Biomarketing, and BioPharm Communications.
In addition, both CBI events yielded front page coverage for the Executive Roundtables we present. The first, in this issue, covers the financial executives view of the financial and accounting professional in pharma for the future. And in July, we will feature the Chief Compliance Officer, as they forge ahead with the recently introduced principles-based approach to policies. All executives share their insights from their companies, both large and small, which provide well-needed insight for our broad readership.
Along with the flagship conferences for our industry-BIO and DIA-Pharmaceutical Executive will gather, on a smaller scale, our very own Editorial Advisory Board experts to discuss trends, gain more cross-functional insight, and leverage their views of our brand-again on the road to bringing readers the best that our multimedia content provides.
Don’t like watching videos or maybe streaming in the office is not allowed? No problem. The Pharm Exec Podcast features interviews with fresh voices from biotech, pharma, and digital health companies. Found on SoundCloud, our 30th episode is with Anna Sundgren, renal disease strategy leader, global medicines development at AstraZeneca, who discusses her personal experience with her mother’s death from renal disease, and the state of renal disease drug development. In another recent episode, Otsuka executives discuss their approach to digital medicine, and you can also listen to interviews with our own editors on stories they have recently reported on.
Last month, I wrote about the many interviews we conduct that have appeared in print. I’m only promoting our offerings a bit. We speak to so many interesting and influential people, I hate to think that even one of their insights gets lost in everyone’s day-to-day hustle and bustle, as well as the many places they go for information. We keep you up-to-date on all of it via e-newsletters and social media. Check out and join our Twitter and Instagram, as well as LinkedIn to make sure you aren’t missing anything from Pharmaceutical Executive. Thanks for reading, watching, and listening.
Lisa Henderson is Editor-in-Chief of Pharm Exec. She can be reached at lhenderson@mmhgroup.com. Follow Lisa on Twitter: @trialsonline
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.